 Benchmark initiated coverage of Biofrontera Inc NASDAQ:BFRI with a Buy rating and 11 price target. The Company specializes in medical dermatology, which recently came public in the U.S. as a carve-out from Germanys Biofrontera AG NASDAQ:BFRA. 